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INTRODUCTION
In breast cancer patients, breast conserving surgery has dem-
onstrated good oncologic and cosmetic results [1,2]. However, 
it still remains difficult to get satisfactory cosmetic results,     
depending on the tumor size, location, and breast volume [3]. 
Breast conserving surgery is performed in breast cancer patients 
requiring radiation therapy, and therefore requires careful     
decision making with regard to any foreign substance planned 
for insertion.
Breast conserving surgery using polyglactin 910 mesh (Vic-
ryl
®; Ethicon Division, Johnson and Johnson, Somerville, USA), 
to create a kind of seroma, showed excellent cosmetic results, 
and relatively few complications. After breast conserving sur-
gery with polyglactin 910 mesh, infection rates of only 3-7% 
have been reported [4]; however, the risk factors and clinical 
outcomes have not been adequately addressed. In this study, 
risk factors for infection and clinical outcomes of patients with 
polyglactin 910 mesh insertion during breast conserving sur-
gery, were analyzed. 
METHODS
From June 2007 to August 2010, patients who underwent 
breast conserving surgery with mesh insertion for breast cancer 
at our institution were retrospectively studied. Patients with 
benign histologic results, or who had follow-up periods less 
than 3 months were excluded from the final analysis, because 
infection generally developed 3 months after operation in our 
study. In all study patients there were no contraindications to 
polyglactin 910 mesh insertion. Polyglactin 910 mesh was     
inserted when severe breast shape deformation was expected 
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Purpose: Breast conserving surgery using mesh can effectively 
fill the defective space, but there is the risk of infection. Methods: 
From June 2007 to August 2010, 243 patients who underwent 
breast conserving surgery with polyglactin 910 mesh insert for 
breast cancer at our institution were retrospectively studied.   
Results: Infection occurred in 25 (10.3%) of 243 patients. When 
comparing the infection and non-infection groups in multivariate 
analysis, there was no significant difference in age, underlying 
disease, preoperative biopsy methods, mass location, axillary 
lymph node dissection, operative methods, neoadjuvant or adju-
vant chemotherapy use, mass size and removed breast volume. 
The infection appeared more common only in patients with body 
mass index (BMI) greater than 25. Infection symptoms occurred, 
on average, 119.5 days after surgery, and the average duration 
of the required treatment was 34.4 days. Out of 25 patients with 
postoperative infection complications, 16 (64%) patients underwent 
incision and drainage with mesh removal, whereas the remaining 
9 (36%) only required conservative treatment. Conclusion: During 
breast conserving surgery, the risk of infection is increased in pa-
tients with high BMI, and should be taken into account when con-
sidering insertion of a polyglactin 910 mesh. Patient’s age, under-
lying disease and perioperative treatment methods were not signif-
icant risk factors for developing mesh infection. Given that most 
infections seem to develop symptoms one month after surgery, a 
long enough observation period should be initiated. Early detection 
and appropriate conservative treatments may effectively address 
infections, thus reducing the need for more invasive therapies. 
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following breast conserving surgery, for instance when relatively 
small breast parenchyma showed large defect, in lower and 
inner breast cancer.
After washing with normal saline, regardless of the size of the 
deficient space, folding scalloped polyglactin 910 mesh com-
pletely wrapped in oxidized regenerated cellulose (Interceed
®; 
Ethicon Division, Johnson and Johnson, Somerville, USA) was 
inserted as one polyglactin 910 mesh, in the shape of a trian-
gle. The mesh was placed without being fixed and the skin was 
sutured in the usual method. Patients who had the mesh inserted 
did not have drains placed and aspiration was not performed, 
even in cases with serous fluid retention, during the follow-up 
observation period. Intravenous antibiotics were administered 
for 3 days after surgery, using a first generation cephalosporin, 
followed by 5 days oral antibiotics. 
Mesh infection was diagnosed by physical examination per-
formed by a breast specialist during the follow-up period, and 
infection was defined as patients requiring treatment more than 
oral and intravascular antibiotics, conservative therapy excluded. 
Complete cure was defined as antibiotic treatments stopped 
and sutures removed. Difference in age, body mass index (BMI), 
underlying disease, preoperative biopsy methods, mass loca-
tion, operation time, operation methods and perioperative 
treatment method were analyzed between the group of patients 
showing postoperative infection and those who did not. In 
addition, symptoms and their time of onset, treatment methods 
and treatment duration were analyzed for the infection group.
RESULTS
Infection occurred in 25 of 243 (10.3%) reviewed patients. 
Average age and underlying disease were not significantly dif-
ferent between patients developing infections and those who 
did not. However, patients with BMI greater than 25 were more 
likely to develop infection (p=0.007). Based on preoperative 
biopsy methods, patients diagnosed with the vacuum-assisted 
biopsy device showed an overall higher incidence in the infec-
tion group (n=3, 12.0%), compared with the non-infection 
group (n=14, 6.4%), but this difference was not statistically 
significant (p=0.248). In both groups, upper-inner quadrant 
breast surgery was most frequently performed. Breast con-
serving surgery for a breast mass in the lower-inner quadrant 
requiring insertion of polyglactin 910 mesh, was more likely 
to develop an infection (p=0.041) (Table 1).
The average operation time was 86.9 minutes and there was 
Table 1. The patients’ clinical characteristics
Characteristics
Non-infection,  
No. (%)
  Infection,  
  No. (%)
p-value
Age (yr)* 47.7±7.8    45±8.0 0.122
   ≥50   93 (42.7)      9 (36.0) 0.339
   <50 125 (57.3)    16 (64.0)
BMI* 22.8±2.8 23.6±2.9 0.172
   ≥25   35 (16.1)    10 (40.0) 0.007
   <25 183 (83.9)    15 (60.0)
Underline disease 
   Hypertension   23 (10.6)      3 (12.0) 0.518
   DM   9 (4.1) 0 (0) 0.370
   CRF   1 (0.5) 0 (0) 0.897
   Hepatitis B   5 (2.3) 0 (0) 0.578
   Thyroid disease   6 (2.8)      2 (25.0) 0.194
Pre-operative biopsy method
   Core needle biopsy 154 (70.6)    16 (64.0) 0.318
   Excision biopsy   27 (12.4)      3 (12.0) 0.628
   Mammotome excision 14 (6.4)      3 (12.0) 0.248
   FNA   23 (10.6)      3 (12.0) 0.518
Right 119 (54.6)    14 (56.0) 0.533
Left   99 (45.4)    11 (44.0)
Tumor location
   UIQ   98 (45.0)    12 (48.0) 0.467
   UOQ   59 (27.1)      4 (16.0) 0.171
   LIQ   27 (12.4)      7 (28.0) 0.041
   LOQ   33 (15.1)    2 (8.0) 0.266
   Subareolar area   1 (0.5) 0 (0) 0.897
Total 218 25 243
BMI=body mass index; DM=diabetes mellitus; CRF=chronic renal failure; 
FNA=fine needle aspiration cytology; UIQ=upper inner quadrant; UOQ=   
upper outer quadrant; LIQ=lower inner quadrant; LOQ=lower outer quad-
rant.
*Mean±SD.
Table 2. The treatment process
Non-infection,  
No. (%)
  Infection,  
  No. (%)
p-value
Operation time (min)* 87.5±23.6 81±23.4 0.235
   <85  100 (45.9) 16 (64.0) 0.066
   ≥85  118 (54.1)   9 (36.0)
Lymph node dissection  0.183
   SLNB or none-LN excision 141 (64.7) 19 (76.0)
   ALND   77 (35.3)   6 (24.0)
Pre-operative staining
   Done   64 (29.4)   9 (36.0) 0.318
   Not done 154 (70.6) 16 (64.0)
Intraoperative re-excision
   Done   32 (14.7)   4 (16.0) 0.525
   Not done 186 (85.3) 21 (84.0)
Peri-operative treatment
   Neoadjuvant chemotherapy 12 (5.5) 2 (8.0) 0.434
   Adjuvant chemotherapy 158 (72.5) 13 (52.0) 0.032
   RT start time
† 108.0±46.5 103.6±43.8 0.653
      ≤ POD 99   62 (28.6) 12 (48.0) 0.042
      ≥POD 100 155 (71.4) 13 (52.0)
Total 218 25 243
SLNB=sentinel lymph node biopsy; LN=lymph node; ALND=axillary lymph 
node dissection; RT=radiation therapy; POD=postoperative day.
*Mean±SD; 
†One patient who refused radiation therapy was exclude from ra-
diation therapy start time analysis.330   Jin Seong Cho, et al.
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no difference in operative time between the infection group and 
non-infection group. When frozen biopsy showed a positive 
margin, no significant difference between the two groups was 
noted whether axillary lymph node dissection, preoperative 
mass stain or interoperative re-excision was performed. Simi-
larly, preoperative chemotherapy was not associated with in-
creased infection risk, but patients who did not receive adjuvant 
chemotherapy had more frequent infection (p=0.032). A pos-
sible explanation for this finding may be that radiation therapy 
was started early, when adjuvant chemotherapy was not per-
formed (p=0.042) (Table 2).
Postoperative biopsy confirmation of either invasive ductal 
carcinoma or carcinoma in situ, and the presence or absence 
of lymph node metastasis did not show any relationship with 
increased infection rate. Likewise, mass size, removed breast 
Table 3. Pathologic characteristics
Characteristics
Non-infection,  
No. (%)
 Infection,  
 No. (%)
p-value
Pathologic result 0.079
    Invasive carcinoma 193 (88.5) 19 (76.0)
    DCIS   25 (11.5)   6 (24.0)
Lymph node metastasis
   Present   64 (29.4)   4 (16.0) 0.117
   Volume of removed 
      breast tissue (cm
3)*
274.1±255.7 240.1±200.1
      <200  116 (53.2) 13 (52.0) 0.537
      ≥200  102 (46.8) 12 (48.0)
   Longest axis (cm)* 9.3±2.8 8.7±2.0 0.294
      <8.5    84 (38.5) 12 (48.0) 0.240
      ≥8.5  134 (61.5) 13 (52.0) 0.521
Tumor size (mm)* 15.8±8.4 18.1±12.1 0.362
   <20  149 (68.3) 15 (60.0) 0.264
   ≥20    69 (31.7) 10 (40.0)
Total 218 25 243
DCIS=ductal carcinoma in situ.
*Mean±SD.
Table 4. Univariate and multivariate analyses of risk factors for mesh in-
fection
Fators
p-value
OR
Univariate analysis  Multivariate analysis 
BMI≥25 0.007 0.004 3.966
Tumor location LIQ 0.041 0.114 2.266
Adjuvant chemotheraphy 0.032 0.683 1.793
RT start time≤POD 99 0.042 0.965 1.006
OR=odd ratio; BMI=body mass index; LIQ=lower inner quadrant; RT=radia- 
tion therapy; POD=postoperative day.
Table 5. Characteristics of individual patients in the infection group
No. Age BMI Symptom
Onset time 
day (mo)
Treatment method
Duration of
treatment (day)
  1 49 21.76 Painful swelling 32 (1) I&D, mesh removal 35
  2 57 28.40 Erythema 191 (6) I&D, mesh removal 82
  3 34 18.97 Erythema 364 (11) Oral antibiotics 6
  4 46 24.14 Erythema 22 (0) Oral antibiotics 29
  5 41 28.31 Erythema 24 (0) I&D, mesh removal 26
  6 49 24.88 Erythema 43 (1) Oral antibiotics 42
  7 53 22.77 Erythema 34 (1) I&D, mesh removal 46
  8 50 23.24 Erythema 174 (22) IV antibiotics 44
  9 51 24.31 Erythema 677 (2) I&D, mesh removal 118
10 38 21.88 Pustular nodule 62 (1) I&D, mesh removal 44
11 52 21.75 Erythema 35 (7) I&D, mesh removal 67
12 34 20.55 Erythema 241 (4) I&D, mesh removal 33
13 63 20.69 Erythema 139 (10) Close drain 15
14 35 25.13 Erythema 332 (10) I&D, mesh removal 33
15 47 19.11 Wound dehiscence 41 (1) I&D, mesh removal 11
16 44 23.73 Erythema 38 (1) I&D, mesh removal 17
17 51 28.19 Erythema 233 (7) I&D, mesh removal 21
18 47 25.10 Erythema 38 (1) I&D, mesh removal 40
19 33 18.29 Pain  38 (1) I&D, mesh removal 42
20 47 25.64 Erythema 62 (2) Oral antibiotics 7
21 43 25.10 Heatness 21 (0) I&D, mesh removal 41
22 47 25.00 Erythema 48 (1) Oral antibiotics 17
23 45 25.01 Discharge  58 (1) IV antibiotics 9
24 29 27.28 Discharge 22 (0) I&D, mesh removal 21
25 44 20.20 Painfull swelling  18 (0) Oral antibiotics 12
BMI=body mass index; I&D=irrigation and drainage; IV=intravenous.Analysis of Infections Occurring in Breast Cancer Patients after Using Mesh  331
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volume and long axis of the removed breast were not related 
to infection rates (Table 3).
Based on univariate analysis, the factors associated with     
increased infection included BMI over 25, masses located in 
the low-inner quadrant, patients who have not undergone   
adjuvant chemotherapy and those who initiated radiation ther-
apy within 100 days postoperatively. When analyzing these 
parameters independently in our multivariate analysis, the BMI 
greater than 25 was the only significant risk factor associated 
with infection (Table 4). 
Infection occurred in 25 patients, with most symptoms       
involving skin redness and pain. The local redness and ten-
derness can distinguish infection from post-radiation dermal 
complication. In 3 patients, wound dehiscence and discharge 
occurred as first symptoms (Table 5). On average, symptoms 
occurred 119.5 days after surgery. Of the 25 patients with infec-
tion, 20 patients (80%) reported symptoms after 30 days, 15 
patients (60%) reported symptoms after 60 days, and 5 patients 
(20%) had symptoms after 6 months. After the symptoms     
onset, 16 patients (64%) underwent incision and drainage with 
mesh removal, whereas 6 patients (24%) were treated with oral 
antibiotics. Intravascular antibiotic treatment was performed 
in 2 patients and closed drainage was performed in one patient. 
For patients with infection, the average duration of treatment 
was 34.4 days. Five patients (20%) were healed by day 15 post-
operatively, whereas in 13 patients (52%) more than 30 days 
were required to clear the infection, of which 3 patients (12%) 
were completely cured only after 60 days of therapy (Table 6).
Table 6. Course of treatment for mesh infections
No. (%)
Onset time of symptoms* 119.54 
   <30 day   5 (20)
   30-59 day 10 (40)
   60 day-6 mo   5 (20)
   6 mo-1 yr   4 (16)
   >1 yr 1 (4)
Treatment methods
   I&D, mesh removal 16 (64)
   Oral antibiotics   6 (24)
   IV antibiotics 2 (8)
   Closed suction drain 1 (4)
Duration of treatment (day)* 34.4
   <15    5 (20)
   16–29    7 (28)
   30–59  10 (40)
   >60    3 (12)
Total 25
I&D=irrigation and drainage; IV=intravenous.
*Mean.
DISCUSSION
Breast conserving surgery has become a standard strategy 
for breast cancer, especially in early breast cancer. However, 
breast conserving surgery without volume replacement can 
lead to cosmetic failure. Reconstructive surgery using either 
abdominal or back muscle (i.e., the transverse rectus abdomi-
nus myocutaneous [TRAM] flap, latissimus dorsi flap, etc.) has 
been the traditional method of volume replacement; however, 
this technique required long operative and recovery times, was 
associated with high medical costs and there was increased risk 
for complications, such as necrosis of the transplanted tissue 
and abdominal wall herniation [5,6]. When breast conserving 
surgery is performed over mastectomy, TRAM is difficult to 
perform. Insertion of the polyglactin 910 mesh has been per-
formed to deliberately form a seroma to fill the defect space. 
This procedure is simple and easy to learn, with decreased   
operative time and less burden to the patient. In addition, after 
3 months, the polyglactin 910 mesh almost dissolves completely 
into the body, so follow up breast cancer imaging can more 
accurately be interpreted [7].
The first report of mesh use in breast cancer was by Largiadèr 
et al. [8] in 1997, where a nylon mesh with greater omentum 
was inserted after full-thickness removal of the breast. The   
insertion of the mesh for cosmetic purposes was described by 
Amanti et al. [9] in 2002, when they reported insertion of the 
polyethylene mesh after mastectomy. Then, in 2005, Sanuki et 
al. [10] published a report of breast conserving surgery using 
polyglycolic acid and oxidized regenerated cellulose mesh       
insert.
After polyglactin 910 mesh insertion, improved patient sat-
isfaction and cosmetics has been proven in several studies [11, 
12]. However, infection after mesh insertion is an area of inter-
est. Infection of mesh material results in breast shape distortion 
after surgery; in addition, postoperative chemoradiation ther-
apy can be delayed if infections occurs. Therefore patients with 
diabetes mellitus or immune dysfunction, who are expected 
to have higher risks for infection, tend not to be offered mesh 
insertion. In this study, the older aged patients with underlying 
disease, who received neoadjuvant chemotherapy after inser-
tion of polyglactin 910 mesh, were compared with healthy pa-
tients. 
The patient’s age was not associated with increased infection 
rates and diabetes patients were not associated with infection. 
In the univariate analysis, insertion of polyglactin 910 mesh 
into the low-inner quadrant breast mass, where is relatively 
small breast parenchyme, was followed by statistically signifi-
cant infection, but the difference was not significant in multi-
variate analysis. 332   Jin Seong Cho, et al.
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There was no statistical difference whether or not a patient 
underwent axillary lymph node dissection; the procedure is 
expected to require a mesh insertion into the inner or lower 
side of the breast, so the incision line for sentinel lymph node 
biopsy or axillary lymph node dissection and for breast paren-
chyma resection was presented independently. Assessment of 
the risk of infection when performing single-incision surgery, 
axillary lymph node dissection and breast conserving surgery 
using polyglactin 910 mesh requires further studies. 
Patients who did not undergo adjuvant chemotherapy ap-
peared to have a higher risk of postoperative infection. This 
finding may be attributable to earlier initiation of radiation 
therapy, although multivariate analysis showed no significant 
difference. However, receiving radiation therapy may lead to 
either dermatitis or mastitis, so more research is needed regard-
ing postoperative infection. 
Post-operative complications, such as bleeding and skin   
necrosis, can relate with mesh infection; however, in this study, 
there was no skin necrosis. We had three cases of post-opera-
tive bleeding after mesh insertion: one patient showing infec-
tion after 32 days and two patients undergoing immediate     
removal of hematoma and polyglactin 910 mesh. Therefore, 
analysis of post-operative complications and mesh infection 
was difficult. 
In this study, the definition for mesh infection required both 
the diagnosis based on physical examination performed by a 
breast specialist and treatment with oral antibiotics, intravascu-
lar antibiotics and drainage. In previous studies, the definition 
of infection was restricted to incision and drainage for treat-
ment. For this reason, this study seems to show a higher infec-
tion risk than previous studies. In this study, the percentage of 
infected patients who had to remove the mesh and undergo 
incision and drainage was 64%. If early diagnosis is made and 
appropriate treatments are initiated conservative treatments 
can cure the infection. 
Based on our univariate analysis, risk factors for mesh infec-
tion included a higher BMI, earlier initiation of radiation ther-
apy after surgery, and tumors located in the inner-lower side 
of the breast. Multivariate analysis of these risk factors, how-
ever, resulted in high BMI as the only significant risk factor. 
Mesh infection was not associated with old age, underlying 
disease, tumor location, adjuvant or neoadjuvant chemother-
apy, or radiation therapy. We consider that perioperative treat-
ment methods and the patients underlying diseases were not 
related with mesh infection, therefore avoiding mesh insertion 
seemed not necessary.
In most patients, symptoms occurred after 30 days, with rare 
instances occurring after 1 year. Adequate follow-up period 
and early detection with appropriate conservative therapies can 
improve the outcome results. 
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